Compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium

A pharmaceutical composition comprising a compound

• or a pharmaceutically acceptable salt, a racemic mixture, a corresponding enantiomer or, if applicable, a corresponding diastereomer thereof,
• wherein:
• R1, R11 and R12 are independently selected from the group consisting of hydrogen, fluoro, chloro, methoxy, trifluoromethyl, methyl and difluoromethoxy, whereby at least one of R1, R11 and R12 is not hydrogen
• B is selected from the group consisting of a residue of formula (II), (III), (IV), (V), (VI) and (VII)
• wherein
• “*” denotes the point of attachment to the remainder of the molecule, and
• R2, R3, R4, R5, R2I, R3I, R4I, R5I, R2II, R3II, R4II, R5II, R2III, R3III, R4III, R5III, R2IV, R3IV, R4IV, R5IV, R2V, R3V, R4V, R5V are independently selected from the group consisting of hydrogen, a linear or branched alkyl having 1 to 3 carbon atoms, fluoro, chloro, bromo, methoxy, ethoxy, propoxy, trifluoromethyl and difluoromethoxy as a therapeutically active substance and a pharmaceutically acceptable carrier and/or adjuvant for use in the treatment and/or prevention of a disease involving the retinal pigment epithelium.